Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks (JACC October 2023-2)

Description

Among 5,403 patients, clopidogrel monotherapy showed a lower rate of the primary composite endpoint than aspirin monotherapy (HR 0.73 [95% CI 0.59-0.90]). The benefit of clopidogrel over aspirin was consistent regardless of TRS 2P (high TRS 2P [>=3] group: HR 0.65 [0.44-0.96] and low TRS 2P [<3] group: HR 0.77 [0.60-0.99]) (P-for-interaction =0.454) and regardless of DAPT score (high DAPT score [>=2] group: HR 0.68 [0.46-1.00] and low DAPT score [<2] group: HR 0.75 [0.59-0.96]) (P-for-interaction =0.662). The association was similar for the individual outcomes. The beneficial effect of clopidogrel over aspirin monotherapy was consistent regardless of clinical risk or relative ischemic and bleeding risks as compared to aspirin monotherapy.

Editors
Editor-in-Chief
Valentin Fuster, MD, PhD, MACC

CME Editor
Ragavendra R. Baliga, MD

Author
Konstantinos Dean Boudoulas, MD, FACC

Important Dates
Date of Release: October 9, 2023
Term of Approval/Date of CME/MOC Expiration: October 8, 2024

Summary


Availability:	On-Demand
	Expires on Oct 08, 2024


Cost:	FREE


Credit Offered:	1 CME Credit 1 ABIM-MOC Point